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And Cancer Too:

Treating Cancer Alongside Other Conditions

by Sunni Hosemann

ancer does not a lways paint
itself onto a blank canvas
of otherwise perfect health.
The picture is often compli
cated by other, sometimes
chronic or severe, illnesses. Given that
most new cases of cancer occur in
peopl,e who are at 1.east 50 years
oU, conditions such as hyperten
sion, chronic
obstructive frul�
i
nary dsease, diabetes, congestive
heart failure, and coronary
artery disease frequently
flredale the cancer diagnosis.
not managed appropriately
before and dU1ing cancer
treatment, these CJYrTl01iJid
conditions couJd have
devastating consequences.
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Controlling lnfedion in Patients with Neutropenia
(Continuedj'T071i page 3)

infection in these patients because
their immunity is low and their
inflammatory response is blunted,
so they don't often give you the same
signs and symptoms as an immune
competent person does," said
Kenneth Rolston, M.D., professor
and chief of the Section of Infectious
Diseases in the Department of
Internal Medicine Specialties at The
University of Texas M. D. Anderson
Cancer Center. Fever or shortness of
breath may be the patient's only
symptom, Dr. Rolston said, so the
tools for making a specific diagnosis
are not always available.
Blood and urine cultures, biopsies
of visible lesions, and imaging tech
niques such as chest x-rays, computed
tomography, and magnetic reso
nance imaging can help identify
some infect.ions, and newer tech
niques that use polymerase chain
reaction analysis and measure
antigens or antibodies for specific
pathogens are also being evaluated.
However, a specific diagnosis is not
made in 40% to 60% of patients
with neutropenia. In these cases,
the patients are still treated with
antibiotics because of the high
probability that an infection exists.
"Infections in patients who are
neutropenic can develop very
quickly, and they can disseminate
or progress very quickly," explained
Or. Rolston. "So although the stan
dard way of managing infections
in patients who are not immuno
compromised is to make a specific
diagnosis and then treat, you cannot
wait for a speci£c diagnosis to treat
patients with neutropenia," he said.
At M. D. Anderson, patients with
febrile neutropenia undergo a
diagnostic workup quickly, and
treatment is started based on which
infectious organisms are anticipated
to be present.
Many different antibiotic, antifun
gal, and antiviral protocols or specific
drugs are available, depending on a
patient's susceptibilily to certain
infections. Or. Rolston emphasized
that different patients qualify for
4 I MD Anderson OncoLog

According to Kenneth Rolston, M.D., professor and chief of the ,'intion of Infectious
Diseases, infections in patients with neutropenia tend to develop ,,nrf spread quickly,
so treatment is often begun before a specific dia.gnosis is made.
different treatment options and that
all of these options should be used
within a single institution rather than
using the same drugs or regimens
to treat everyone.
'This way, bugs encounter different
defenses, and they don't become
resistant to any one particular
option," he said. Among the many
antibacterial regimens used for
the treatment of infections at M. D.
Anderson are aminoglycosides plus
j3-lactam, vancomycin plus j3-lactam,
quinolones (which are also used for
prophylaxis), and broad-spectrum
penicillins. In addition to antibiotics,
growth factors such as granulocyte
colony�stimulating factor and granu
locyte-macrophage colony-stimulat
ing factor are sometimes given to
boost a patient's immune system,
as are white blood cell transfusions
and immune globulins.
Researchers in the Depa1-tment
of Health Services Research and in
the sections of Infectious Diseases,
Infection Control, and General
Internal Medicine within the Depart
ment of lnternal Medicine Special
ties have focused on the problem

of neutropenia, ncl macle important
contributions to < unent clinical
pra.ctice guideli1 e,.
At M. D. Ande 'Son, patients at
low risk are treat ed in the outpatient
setting with oral ather than intrave
nous antibiotics h·hen appropriate.
"More than 90% of patients respond
in the outpatient setting, and the
10% who don't respond have a
prolonged fever hnt don't get into
trouble with septic shock, intensive
care unit admi%ions, or major
complications," said Dr. Rolston.
Technological advances may make
prevention and trcatment of infec
tions easier, and the infections may
become more responsive, but Dr.
Rolston does not anticipate that the
problem will go away.
"I see it changing," he said. "I see
the playing field changing, but the
key is going to be to try to develop
techniques and strategies that produce
anti tumor responses without causing
such desu·uction of the immune
system."•
FOR MORE INFORMATION,

at (713) 792-6830.

contact Dr. Rolston
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How to Talk with Your Doctor

vances in cancer treatments and the explosion of cancer
.. mean
research and clinical trials in .the past few years
more treatments are availabl,efor patients with cancer.
Often, patients are faced with several treatment options
that could l,ead to the same outcome but have different limitations
and side effects. So how do you know which treatment is right for
you? With the hPlp ofyour doctor and the support off amily and
friends, you can gain a better understanding ofyour disease and
make informed rlPCisions about your treatment.
Communicatio1 mvolves not
only understanding what your doctor
tells you but also unking your needs
and wants clear to ,our doctor. Below
are some tips fo1 talking with your
doctor that will h( Ip you leave his or
her office in fornwd of your options
and able to make important
decisions.

Before your appointment:
■ Decide what 1,pe of doctor

patient relationship vou want. Do
you want your doctor to describe
your options and It ·we the decisions
to you, offer suggi·stions for the
treatment plan. or make the deci
sions for you? Be mre to let your
doctor know which kind of relation
ship you prefer so he or she ca11
act accordingly.
■ If you decide that you want to
make some or all of the decisions
regarding your treatment, you will
need to be prepared. Do as much
research as possible through sources
such as medicaljournaJs, Internet
sites, and your telephone. Good
online sources of information are
the Amer ican Cancer Society
(www.cancer.org), the National
Cancer Instit ute (www.cancer.gov�,
and the Cancer Information Service
(CIS) (cis.nci.nih.gov). CIS also
r
has a toll-f ee telephone number

( 1 ·800-4-CANC ER) .

■ Write all the questions that you

have on a notepad, and take it with
nt. Be sure to
yo u to your appointme
·
s, an d don 't
stion
que
r
you
ask all of

be embarrassed about writing down
your doctor's answers. Doctors
appreciate a patient's desire for
knowledge and communication.
Here are some questions you might
consider asking:

ti
ti

WltM if m;' �Mrifl
wware.,K<f-tY�

ti

optwns!

what are, roau,

Waly rul,e,,
!

effects of�tr�
ti wutr be,abl,e,to CAYYf D#f/
,wymai, ad:iv-it:iN dur�
tr�1

ti' wutrbe,hor�
J.uri.H.j the, aurre, Dj Ho/
tr�r
■ Although you will probably see
several doctors during the course of
your cancer treatment, it may be helpful
to choose one doctor as your primat)'
source of information and establish a
level ofLrusl with that doctor. This will
allow you to feel secure in the recom
mendations of your doctor and in yow
tYcatment plan.
At your appointment:

■

Bring a friend or family mem
ber to the appointment with you for

moral support and to help you ask
questions and remember important
information.
■ If you don't understand some
thing your doctor tells you, keep
asking questions until you do.
Understanding your options is vital
to helping you make decisions that
arc right for you.
■ Tape record the visit so that you
can listen again at home. This way,
you can replay the doctor's words as
often as you want to increase your
level of understanding. Just be sure
to ask the doctor's permission to
record first.
■ Before your appointment ends,
make sure you know what the next
step in your treatment plan is. Will
you need to set up another appoint
ment? Arrange for tests at another
location? Make an appointment
with another doctor?

After your appointment:
■ Based on what your doctor told

you during your appointment, you
may want to conduct more research
on the particulars of your u-eatrnent
options when you get home.
■ What if you think of one more
question after you arrive home from
your appointment? Before leaving
your doctor's office, find out how
be or she prefers tO communicate
perhaps by telephone or e-mail. •

For ,nore information, contact
your physician or contact the
lvf. D. Anderson Information Line:
({) (800) 392-161 1 within
the United States, or
({) (713) 792-6161 in Houstrm
and outside the United States.
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